UNSPSC 51294505: Femoxetine

This classification denotes a serotonin agonist with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y719ZLX8C, chemically known as piperidine, 3-((4-methoxyphenoxy)methyl)-1-methyl-4-phenyl-, (3r-trans)- but generally known as femoxetine, which bears US NIH Compound Identifier 43103. European Medicines Agency schedules Femoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07530MIG.

UNSPSC 51294505 Femoxetine is a Commodity code that state and local governments use to classify pharmaceutical procurement, though the most recent activity under this code shows a significant mismatch: Seminole County, Florida posted an IFB for naloxone and safe drug deactivation systems rather than femoxetine specifically. The solicitation (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The county required vendors to include all shipping and delivery costs in their bids, submit electronically through the county's e-Procurement Portal, and comply with drug-free workplace certification, E-Verify requirements, and specified insurance coverages including workers' compensation, commercial general liability, and professional liability. The initial contract term was two years with a one-year renewal option and included a three-month probationary period allowing termination with or without cause. Procurement activity under this Commodity code appears limited to county health and community services agencies focused on opioid response and harm-reduction initiatives rather than traditional pharmaceutical inventory.

The recent opportunity comes from Seminole County, a mid-sized Florida jurisdiction with community health purchasing authority. Geographic distribution under this code cannot be characterized beyond the single Florida posting; no other state or local jurisdictions appear in the recent-opportunities record. The mismatch between the code's nominal scope (femoxetine, a serotonin reuptake inhibitor) and the actual procurement (naloxone and drug deactivation systems) suggests either miscoding in the county's procurement system or a narrow application of this Commodity code to emergency-response pharmaceuticals rather than psychiatric medications. Business development professionals should verify whether their firm's pharmaceutical offerings align with harm-reduction and opioid-response procurement rather than assuming traditional antidepressant-class inventory demand.